Table 1.
Summary of potential therapies for COVID-19.
| Therapies | Mode of action | Trial/Phase (as of 09/20/2020) | ||
|---|---|---|---|---|
| Tocilizumab | IL-6 receptor inhibitor | NCT04445272, Phase 2 | ||
| Hydroxychloroquine and Chloroquine | Regulation of pH values and immunity, interference of glycosylation | NCT04261517, Phase 3 | ||
| Baricitinib | JAK-STAT pathway inhibitor | NCT04358614, Phase 2/3 | ||
| Anakinra | IL-1 receptor antagonist | NCT04443881, Phase 2/3 | ||
| Glucocorticoids | Immunoregulator | NCT04244591, Phase 2/3 | ||
| Intravenous immunoglobulin | Pooled IgG to block inflammatory | NCT04354831, Phase 2 | ||
| Zinc | Inhibition of RNA polymerase and regulation of inflammation | NCT04370782, Phase 4 | ||
| ACEI/ARB | RAAS inhibitor | NCT04353596, Phase 4 | ||
| Vitamin D | Immunoregulator and RAAS regulator | NCT04482673, Phase 4 | ||
| IFNβ | Anti-viral medicine and immunoregulator | NCT04343768, Phase 2 | ||
| IFNλ | Anti-viral medicine and immunoregulator | NCT04343976, Phase 2 | ||
| Atorvastatin | Lipid-lowering medicine | NCT04486508, Phase 3 | ||
| Ulinastatin | Protease inhibitor | NCT04393311, Phase 1/2 | ||
| Mesenchymal stem cells | Immunoregulator | NCT04288102, Phase 2 |